COMMUNIQUÉS West-GlobeNewswire

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
25/10/2018
The Eye Want 2 Know digital resource helps patients and their families in the U.S. living with an inherited retinal disease (IRD) learn about genetic testing and includes a “Find A Provider” tool to locate health care [...]
Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
25/10/2018
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after the market close on [...]
Avadel Pharmaceuticals to Report Third Quarter 2018 Financial Results
25/10/2018
DUBLIN, Ireland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, [...]
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
25/10/2018
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of [...]
VANC Pharmaceuticals Inc. Will Change Its Name to Avricore Health Inc. Reflecting Its New Initiatives and Focus
25/10/2018
VANCOUVER, B.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. ( “VANC” ) is pleased to announce that it will seek TSX Venture Exchange (the “TSXV”) approval to change the name of the Company to Avricore [...]
Integrated Cannabis Company, Inc. Enters into Licensing Agreement for Cannabidiol (CBD) Gummy Formulation
25/10/2018
VANCOUVER, British Columbia, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ”), is pleased to announce an agreement to license Cannabidiol (CBD) [...]
Ossur Hf : Interim report Q3 2018
25/10/2018
Announcement no. 63/2018 Interim report Q3 2018 25 October 2018 Highlights Organic sales growth of 7% in Q3 2018 and 5% in USD. Organic sales growth of 5% in 9M 2018. The prosthetics segment grew 11% organic in Q3 2018 [...]
Nexstim secures Business Finland funding for the development of wireless EMG devices
25/10/2018
Nexstim secures Business Finland funding for the development of wireless EMG devices The development project, to be funded by Business Finland, is part of ELASTRONICS, the largest research project in the field of [...]
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
25/10/2018
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and [...]
Rule 2.9 Announcement
25/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 25 October 2018 [...]
VALNEVA Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15
25/10/2018
Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15 Saint Herblain (France), October 25, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech [...]
VALNEVA reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme
25/10/2018
Valneva reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme Saint Herblain (France), 25 octobre 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie [...]
Vistin Pharma ASA : 11 per cent revenue growth in third quarter 2018
25/10/2018
Oslo, Norway, 25 October 2018 Vistin Pharma delivered a revenue growth of 11 percent from NOK 46.7 million in the third quarter 2017 to NOK 51.7 million in the third quarter 2018. The underlying demand for metformin is [...]
argenx reports third quarter 2018 financial results and provides business update
25/10/2018
October 25, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
25/10/2018
Regulated information Gosselies, Belgium, 25 October 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
25/10/2018
Information réglementée Gosselies, Belgique, le 25 octobre 2018, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
25/10/2018
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 [...]
Oncolytics Biotech® Establishes New At-The-Market Facility
25/10/2018
CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus that turns cold [...]
LeMaitre Vascular Acquires Cardial Business of BD
24/10/2018
BURLINGTON, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it has acquired the assets of Cardial, a subsidiary of BD (Becton, Dickinson & Company), located in [...]

Pages